WT1 and metastatic neoplasm: Our finding indicates that the fusion signature remains important in recurrent/metastatic tumors indicates that a EWSR1-WT1 targeting therapy such as lurbinectedin and trabectedin, or an antisense oligonucleotide may be effective in both primary and recurrent DSRCTs.